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A DYNASTY WEANED FROM BIOTECHNOLOGY: 
THE EMERGING FACE OF CHINA 
INTRODUCTION 
Although China has been slow to revolutionize its intellectual prop-
erty laws by Western standards, the recent amendments made to this 
body of law combined with their expanding legal system have nonethe-
less allowed China to successfully participate in the multi-billion dollar 
industry of biomedicine. Through the use of joint ventures, the Chinese 
have lured approximately 1,500 foreign companies into the area of bi-
omedical technology .1 These companies will produce new bi-
opharmaceuticals with an estimated market value of billions worldwide. 
Since China has invested in biotechnology for the last eight to ten years 
and has simultaneously renovated its intellectual property laws, the 
country has brilliantly enabled itself to wholly embrace an extremely 
profitable industry. This note will explore the likelihood of China's suc-
cess in biotechnology and examine the potential difficulties that it may 
face. 
I. BIOTECHNOLOGY DEFINED 
Biotechnology is the application of scientific and engineering prin-
ciples to the processing of materials by biological agents to provide 
goods and services.2 More simply stated, biotechnology is the engineer-
ing and technology of the interaction between man and machines. 3 In 
the field of biomedicine, the biotechnology industry uses the genetically 
based characteristics in microorganisms and animals to create drugs and 
drug therapies.4 These drugs may prevent, cure or in some way alleviate 
diseases. Biomedical research has produced drugs to treat cancer, hepa-
titis B, asthma, AIDS and numerous other afflictions.5 As a result of 
these medical breakthroughs, there has been an increased need for cul-
ture and plant stock collections which can provide the basic source ma-
terial for later genetic modification of existing organisms. The result of 
a genetic modification may be the discovery of a new cure or treatment 
for a disease. 
1. Chinese/European Collaboration, BIOTECHNOLOGY Bus. NEWS, June 3, 1994, at 14. 
2. ALAN T. BULL ET. AL. , BIOTECHNOLOGY: INTERNATIONAL TRENDS AND PERSPECTIVES 21 
(1982). 
3. AMERICAN HERITAGE DICTIONARY OF THE ENGLISH LANGUAGE 190 (3d ed. 1992). 
4. Akim F. Czmus, Biotechnology Protection in Japan, the European Community, and the 
United States, 8 TEMP. INT'L & CoMP. L.J. 435 (1994). 
5. Id. at 436. 
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Biotechnology has also been utilized to treat growing environmen-
tal and agricultural concerns. Several companies, for example, have 
used biotechnology to produce an insecticidal protein that is effective 
against certain harmful insect species.6 In addition, many companies are 
genetically engineering animals and plants to either produce a high yield 
or to increase quality .7 Due to the substantial benefits already incurred 
from this area, the world has come to rely on biotechnological research 
for advances in medicine, pharmacology, and food production. 
II. THE DEVELOPMENT OF INTELLECTUAL PROPERTY PROTECTION FOR 
BIOTECHNOLOGY IN CHINA 
In both China and the West, intellectual property law began not as 
effort to provide incentives to creators by establishing a system of com-
pensation and protection for their work, but rather as an incentive not to 
publish heterodox materials. 8 In England, for example, the Crown lim-
ited the unauthorized copying of books due to their desire to provide 
printers with an incentive not to publish materials against the state inter-
est.9 Similarly, in Imperial China, restrictions on the unauthorized re-
production of certain books were for the maintenance of imperial 
legitimacy and power. 10 The seventeenth and eighteenth centuries in the 
West, however, brought the development of intellectual property law as 
we now know it; the supplying of authors and inventors with a property 
interest in their creations. I I China, on the other hand, under Confucian 
ideology, established a disdain for commercial profit based on the belief 
that true scholars wrote for edification and moral renewal. In fact, there 
was a general attitude of tolerance, or indeed willingness, on the part of 
the great Chinese painters towards the forging of their own works for it 
demonstrated the quality of the work and the creator's degree of civility 
and understanding. I 2 Thus, China's laws concerning intellectual prop-
erty developed far differently from those of the Western states, appear-
ing not to resemble Western laws again until centuries later in the early 
1980's. 
6. Eco gen Signs Chinese Collaboration, BIOTECHNOLOGY Bus. NEws, June 4, 1993, at 17. 
7. Czmus, supra note 4, at 436. 
8. William P. Alford, Comment, Don't Stop Thinking About Yesterday: Why There Was No 
Indigenous Counterparts to Intellectual Property Law in Imperial China, 7 J. CHINESE L. 3, 4 
(1993) 
9. Id. at 9. 
10. Id. at 3. 
11. Id. at 9. 
12. Alford, supra note 8, at 17. 
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Accordingly, it was not until 1985 that China adopted its first pat-
ent law to facilitate trade and establish a legal framework for foreign 
exchange. 13 The law provided for the granting of patents in three areas: 
(1) inventions for a 15 year term; (2) utility models; and (3) designs for a 
5 year term, renewable for an additional 3 years. 14 The 1985 Patent Law 
was intended to reassure foreigners involved in technology license 
agreements that industrial designs not yet publicly disclosed would have 
legal protection, and to promote the development of science and technol-
ogy for the needs of modemization. 15 The drawback of the 1985 Patent 
Law was that it provided little protection to pharmaceutical and chemi-
cal companies and it did not recognize services. 16 
Then, in 1991, China revised the 1985 Patent Law. Although the 
amendments were somewhat helpful, foreign states felt that there was 
not adequate protection for their works in China. Therefore, on January 
17, 1992, the United States and China signed a Memorandum of Under-
standing (hereinafter "MOU") to solve these problems. In compliance 
with MOU, China made another set of amendments to its patent law in 
1993. Among the most substantial changes were the extension of the 
duration of patent protection and the enlargement of patent protection to 
new pharmaceutical and chemical inventions. 17 Although China did not 
permit the patenting of plant and animal varieties, it did permit patents 
on microbiological processes and their products. 18 This new law should 
encourage investment in biotechnology research and development in 
China and is expected to cause an increase in the importation of chemi-
cal and pharmaceutical products. 19 Thus, by drastically changing its in-
tellectual property laws in a period of only eight years, China is clearly 
seeking to stimulate scientific and technical personnel to produce cre-
ations and to attract foreign firms. 
A. Two Means of Patent Law Enforcement in China 
The government of China has expended significant efforts to ac-
commodate the increasing volume of patent litigation by creating a spe-
cial intellectual property division of the People's Intermediate Court in 
13. Harnideh Ramjerdi & Anthony D' Amato, The Intellectual Property Rights la.ws of the 
People's Republic of China, 21 N.C. J.INT'L. & CoM. REa. 169, 175 (1995). 
14. Id. at 176. 
15. Id. at 176. 
16. Id. at 176. 
17. Id. at 177. 
18. Davis Hill &Judith Evans, Comment, Chinese Patent la.w: Recent Changes Align China 
More Closely With Modem International Practice, 27 GEo. WASH. J. INT'L & EcoN. 359, 364 
(1993-1994). 
19. Id. at 361. 
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Beijing. 20 Instead of soliciting judges from China's old cadre system, 
the government sought to staff the intellectual property courts with a 
new contingent of judges.21 China has followed an identical procedure 
in the courts of several provinces, municipalities and economic zones. 22 
The increased volume of lawsuits demonstrates a growing confidence in 
the ability of China to enforce its intellectual property laws. Since the 
culture has a predominant aversion to litigation, 23 China has also offered 
other means of dispute resolution. Plaintiffs may seek conciliation, me-
diation, arbitration or settlement through the Administrative Authorities 
for Patent Affairs. 24 Through this system, adversaries in a patent dispute 
may rely on government officials to resolve their disagreements. 25 The 
Authorities have a strong local presence and connections to other local 
agencies which help them to make settlements without proceeding to the 
courts. In addition, the Administrative Authorities have concurrent ju-
risdiction with the People's Courts over patent infringement actions and 
have the power to order monetary compensation or an injunction against 
the infringer. 26 
While this picture of China's ability to enforce its intellectual prop-
erty laws appears very bright, it is important to remember that the entire 
concept of patentable intellectual property is relatively new to China. 
Many Chinese citizens and businesses are not aware of their right to 
protect intellectual property.27 In addition, the judges who preside over 
intellectual property disputes are typically inexperienced law school 
graduates because no older class qualified to hear such a dispute exists. 28 
Moreover, investigations and dispute settlements are costly, time-con-
suming and complicated, and there is a shortage of Chinese lawyers 
trained in intellectual property law. 29 China is also riddled with corrup-
tion, causing regulations to be interpreted inconsistently from one gov-
ernment agency or ministry to the next. 30 As evidence of this 
widespread corruption, the United States Trade Representative reported 
that the estimated losses due to Chinese intellectual property infringe-
20. Id. at 372. 
21. Id. at 372. 
22. Id. at 372. 
23. Id. at 373. 
24. Id. at 373. 
25. Id. at 364. 
26. Id. at 364. 
27. Meredith A. Harper, International Protection of Intellectual Property Rights in the 
1990's: Will Trade Barriers and Pirating Practices in the Audiovisual Industry Continue, 25 CAL. 
W. lNT'L L. J. 153 (1994). 
28. Id. 
29. Id. 
30. Id. 
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ments in 1993 alone were $50 million. 31 Thus, the legal system that 
appears effective on paper is often futile in reality, spreading alarm to 
foreign investors who are seeking intellectual property protection over 
their technology transfers. As a result, China initiated a nationwide 
campaign to publicize the system of intellectual property protection and 
to educate and train professionals in this field. 32 Therefore, while China 
is to be applauded for the enormous quantity of positive changes that it 
has made in intellectual property law in an extremely short period of 
time, it is unrealistic to expect China's new system to function smoothly 
at the outset. 
III. THE STATUS OF INTERNATIONAL INTELLECTUAL PROPERTY 
PROTECTION FOR BIOTECHNOLOGY AND CHINA'S ROLE IN 
THE INTERNATIONAL ARENA 
In general, there are two prevalent views evident in the interna-
tional conventions that address the subject of biotechnology. Private in-
dustry in developed countries, who typically produce superior biotech 
products, prefer the most expansive set of rights to protect their new 
technologies.33 Developing countries, on the other hand, want pri-
vate34industry in developed countries to surrender certain rights in con-
sideration for the benefits to be realized under a universal patent 
system.35 Furthermore, developing countries would like to receive the 
transfer of new biotechnologies without having to compensate the devel-
oped states.36 Without the ability to receive free technology transfers, 
most developing countries could not afford to pay for the rights to costly 
biotech products. In addition, developing countries would also like to 
exclude living organisms from the scope of protectable subject matter 
for a significant percentage of genetic material used in bioengineering 
new plants and animals is native to their countries.37 
The World Intellectual Property Organization (hereinafter WIPO) 
was created on July 14, 1967 as a specialized agency to the United Na-
tions.38 WIPO was constructed as an administrative body to oversee the 
31. Id. at 165 
32. Hill and Evans, supra note 18, at 371. 
33. David G. Scalise & Daniel Nugent, Comment, International Intellectual Property Pro-
tections for Living Matter: Biotechnology, Multinational Conventions and the Exception for Agri-
culture, 27 CASE W. REs. J. INT'L L. 83, 105 (1995). 
34. Id. at 105. 
35. Id. at 107. 
36. Id. at 111. 
37. Id. at 107. 
38. Convention Establishing the World Intellectual Property Organization, July 7, 1967, 828 
U.N.T.S. 3. 
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Paris Union on the Protection of Industrial Property and to provide a 
forum to harmonize future intellectual property laws. Since 1967, 
WIPO has convened four diplomatic conferences to revise the law. 
WIPO primarily caters to developing states by including provisions that 
would require technology transfers to developing countries, authorize 
compulsory licensing of protected technology and other substantial limi-
tations on the rights of patent holders. In the same vein, WIPO refuses 
to include new plant varieties within the scope of patent protection, 
which blocks adequate intellectual property protection in biotechnologi-
cal advancements. 39 WIPO also excuses the obligation to compensate 
the inventor, which denies biotechnology companies the ability to re-
ceive a return for their investments in the research and development of 
new technologies.40 As a result, the developed states of North America, 
Europe and Asia do not endorse WIPO's efforts.41 
China, on the other hand, joined WIPO in 1983 to demonstrate its 
intention to meet international standards of intellectual property protec-
tion. 42 Furthermore, China's ratification of WIPO occurred at approxi-
mately the same time as the emergence of its new patent laws. These 
two dramatic developments, coupled with China's recent biotechnology 
activity, clearly support the idea that China has strategically planned for 
the emergence of a highly significant biotechnology industry. 
A second multilateral treaty that concerns biotechnology is the 
Convention on Biological Diversity.43 Formed in 1992, the Convention 
aimed to conserve biological diversity, maintain the sustainable use of 
biological components, and to promote the fair and equitable sharing of 
benefits arising out of genetic resources.44 Despite the United States' 
refusal to adopt the treaty at that time, 162 other countries have agreed 
to its terms. While the Clinton Administration supported most of the 
treaty's goals, the U.S. nevertheless could not accept the idea of the 
"equitable share," which would force inventors to transfer their technol-
ogies to developing countries without compensation. The treaty also 
suggested that any income earned from the sales of technology be shared 
with the country that contributes the biological material.45 The concept 
of shared income was borne out of an international concern that bi-
39. Scalise and Nugent, supra note 31, 107. 
40. Id. at 107. 
41. Id. at 107. 
42. Laurence P. Harrington, Note, Recent Amendments to China's Patent Law: The Em-
peror's New Clothes, 17 B. C. !Nr'L & CoMP. L. REv. 337 (1994). 
43. Convention on Biological Diversity, June 5, 1992, S. TREATY Doc. No. 20, 31 I.L.M. 
818 (1993). 
44. Id. 
45. Scalise and Nugent, supra note 31, at 110. 
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otechnological and pharmaceutical corporations of developed states 
were using indigenous flora and fauna from developing countries to 
manufacture their discoveries.46 The founders of the treaty had observed 
foreign companies exploit and profit from the resources of developing 
countries, who lacked the economic strength to buy the new technolo-
gies made from their own raw materials.47 
On June 4, 1993, the Clinton Administration signed the treaty, but 
later submitted a letter of interpretation securing the U.S. position on 
technology transfers.48 The letter announced that transfers of proprie-
tary technology would occur only at the discretion of, and with the vol-
untary consent of the owner of the technology.49 While the international 
community greatly resented the United States' unilateral renegotiation of 
the treaty, it is important to note that if the biotechnology industry per-
ceives low economic returns on an investment due to an international 
convention, then little money will be invested in that area, thereby de-
creasing the possibility for the creation of new drugs or vaccines. 
China signed the Convention on Biological Diversity on June 11, 
1992. 50 While China would undoubtedly like to see the biotechnology 
industry expand, it also has a need to protect itself from foreign exploita-
tion. Many of the new biopharmaceuticals are derived from plant and 
animal life native to the Chinese highlands.51 Therefore, if China fails to 
procure protection from global treaties, foreign companies may com-
pletely exploit Chinese flora and fauna without supplying compensation 
to the Chinese. Besides relying on treaties for protection, China has 
initiated numerous joint ventures to circumvent the dilemma of at-
tracting foreign research and investment in biomedicine without losing 
all of its rights to the final product. 
The General Agreement on Tariffs and Trade (hereinafter GA TT) 
was established in 194 7. GA TT has a division devoted exclusively to 
intellectual property issues, aptly entitled the agreement on Trade Re-
lated Intellectual Property Rights (hereinafter TRIPS).52 TRIPS seeks to 
assist the developed countries in receiving adequate intellectual property 
protection for biotechnology. Since the United States loses an estimated 
$60 billion annually from patent violations by developing countries, it 
46. Id. at 110. 
47. Id. at 111. 
48. Id. at 112. 
49. Id. at 112. 
50. Convention on Biological Diversity, supra note 43, at 1004. 
51. Biotechnology Pro.file: A New Industry Mushrooms, HoNG KONG INDUSTRIALIST, May 1, 
1997. 
52. General Agreement on Tariffs and Trade, Oct, 30, 1947, 61 Stat. A-11, T.I.A.S. 1700, 55 
U.N.T.S. 194. 
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has become an avid supporter of TRIPS.53 As a result of the U.S. en-
dorsement, TRIPS has been widely embraced by developed states like 
Japan and the European Community, who have joined the United States 
in their desire for a universally accepted system of intellectual property 
protections.54 In 1990, TRIPS proposed to authorize patents for living 
organisms and biological processes which would also encompass micro-
organisms, seeds, plants and animals. 55 The developing states, however, 
have opposed GA TT' s attempt to cover patent issues, and would rather 
see these disputes settled in WIPO. 
In addition, the developing countries have made their support of 
TRIPS contingent upon the removal of microorganisms and microbio-
logical processes for the production of plants and animals as patentable 
subject matter. These countries want to narrow the patentable area of 
biotechnology so that only living organisms and biological processes 
that are achieved by traditional breeding methods are protected. 56 Con-
sequently, the developing states want biopharmaceuticals excluded from 
intellectual property protection, which is the area of biotech that has the 
greatest potential for commercial gain. 
In the spring of 1996, the World Health Organization (hereinafter 
'WHO') called for the clarification of whether or not TRIPS protected 
the patent rights of biotechnology processes and products. 57 While 
TRIPS has made the patenting of pharmaceuticals compulsory, the 
agreement does not specify whether biotech processes should be pat-
ented, such as the replication of a naturally existing gene for a human 
protein. 58 As a result, TRIPS may undergo changes in the next four 
years. In the meantime, WHO will be pressing for amendments to have 
TRIPS clarify its position on biotechnology. 59 
The development of China's patent law has enabled it to conform 
with the GATT agreement on TRIPS.60 Since China is currently in the 
process of cultivating and expanding its biotechnology industry, China 
has not ascribed to the views of the other developing countries, who are 
against intellectual property protection for biopharmaceuticals. Rather, 
53. Agreement on Trade-Related Aspects oflntellectual Property Rights, Apr.15, 1994, Mar-
rakesh Agreement Establishing the World Trade Organization, Annex 1 C, LEGAL INSTRUMENTS-
REsUL TS OF THE URUGUAY ROUND vol. 31; 33 l.L.M. 81 (1994). 
54. Scalise and Nugent, supra note 31, at 114. 
55. Id. at 114. 
56. Id. at 115. 
57. WHO Wants Patent Confusion Cleared Up, BIOTECHNOLOGY Bus. NEws, Apr. 10, 1996, 
at 2. 
58. Id. 
59. Id. 
60. Hill and Evans, supra note 18, at 359. 
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China has sought to prove that it is ready to comply with modem inter-
national practice in the enforcement of intellectual property protection.61 
In addition, China would not support the views of the developing coun-
tries, for such support would essentially block both the establishment of 
their biopharmaceutical industry and the profits that could be derived 
therein. 
China has also become a member of the Patent Cooperation Treaty 
(hereinafter PCT) which was unanimously approved at the plenary ses-
sion of the 20th General Assembly of the PCT in September 1992. 62 
Since complying with the PCT, China is performing international patent 
searches and preliminary examinations.63 China's participation in this 
treaty and its willingness to enter into international searches is yet an-
other example of China's drive to compete in the global market of 
biotechnology. 
Furthermore, China has shown support for the International Centre 
for Genetic Engineering and Biotechnology (hereinafter I CG EB) based 
in Geneva. The ICGEB was also established by the United Nations In-
dustrial Development Organization in 1987 to create biotech discoveries 
in developing countries. 64 The I CG EB has recently signed a number of 
licensing agreements with industries in its member states to transfer 
technology that could lead to new products being manufactured by de-
veloping countries.65 
As a result of China's participation in these international agree-
ments regarding the intellectual property protection of biotechnology, 
China has begun to demonstrate to the international community that it 
has not only been willing to revamp its laws in favor of modem practice, 
but has also been willing to become an international figure in the indus-
try. The massive reconstruction of Chinese law and the Chinese acces-
sion to global treaties should not be lightly discounted when one 
considers that China's former isolationist policies had dominated its for-
eign relations law for centuries. Thus, the dramatic shift in Chinese for-
eign policy and intellectual property law should secure China a 
successful position in the field of biotechnology, provided that China 
can continue to evolve its internal political system. 
61. Id. at 359. 
62. Patent Cooperation Treaty, June 19, 1970, 28 U.S.T. 7645, 1160 U.N.T.S. 230. 
63. Hill and Evans, supra note 18, at 359. 
64. New Push for Biotech Products in Developing Countries, BIOTECHNOLOGY Bus. NEws, 
Mar. 12, 1996, at 3. 
65. Id. 
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IV. THE EMERGENCE OF CHINA'S BIOTECHNOLOGY INDUSTRY 
China has devoted a decade of governmental investment in its bi-
omed/biotech industry with the hopes of attaining substantial capital div-
idends in its commercial applications. This year China announced plans 
to raise its biomedical industry level to that of Wes tern standards by 
2004. 66 In order to achieve this end, the Chinese Pharmaceutical Ad-
ministration determined that it would focus future research on genetic 
and protein engineering.67 Although many of China's domestically pro-
duced biomedical products are adaptations of existing foreign developed 
technology, China has recently created government programs designed 
to help research institutions commercialize their work. 68 Coupled with 
the funding for these research institutions, China has also striven to up-
date its intellectual property protection in order to provide an environ-
ment suitable for the biomed/biotech industry. Over the last few years, 
China has attracted nearly 1,500 foreign funded biopharmaceutical en-
terprises amounting in a $4.1 billion capital investment.69 Furthermore, 
seven national level research and development centers and laboratories 
have been established in Shanghai and six national engineering research 
centers are currently under construction there.70 As a result of these new 
research and development centers, Shanghai has been labeled the most 
important "pharmaceutical valley" in China, aiming to generate $1.2 bil-
lion in industrial output by 2000.71 
China has also developed extensive state programs to help imple-
ment their goal of making the biotechnology and pharmaceutical indus-
tries a priority for growth. The Chinese Academy of Sciences has 
provided $20 million for 40 research projects in biomedicine for the past 
five years.72 The projects have aided in the development of hepatitis B 
vaccines, interleukin-2, interferon alpha, and other specialist products.73 
In addition, China's State Science and Technology Commission (herein-
after SSTC) is responsible for the analysis of science and technology's 
role in society and for general management and coordination among var-
ious ministries and agencies.74 The SSTC comprises six programs 
66. Development of Biomedicine in China, MARKETLETIER, London, Sept. 8, 1997. 
67. Id. 
68. Andrew Beckman, Biomed & Biotech New Business Opportunities in China (PRC), BI-
OMEDICAL MARKET NEWSL., Apr. 1, 1996. 
69. Dan Gallagher, China Offering Biotech Firms Big Opportunities, SAN DIEGO DAILY 
TRANSCRIPT, June 17, 1997 at A 1. 
70. China to Focus on Biotech, BIOTECHNOLOGY NEwswATCH, Jan. 20, 1997. 
71. Biotech Gets Top Priority in Zhangjiang, BIOTECHNOLOGY NEWSWATCH, Nov. 4, 1996. 
72. Development of Biomedicine in China, MARKETLETTER, London, Sept/ 8, 1997. 
73. Id. 
74. Beckman, supra note 68. 
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which support biomed/biotech development and commercialization. 
The first program is entitled China's Key Technologies R&D Program, 
which is organized in five-year time blocks.75 By 1991, China had es-
tablished 7 4 national key labs in higher education and research insti-
tutes. The following five-year plan (1991-1995) set goals in the biomed/ 
biotech field to develop new biochemical reagents, and genetically engi-
neered vaccines.76 
The second program under the SSTC is entitled the "863" program 
because it was announced by Deng Xiao Ping in March 1986, listing 
biotech as one of seven targeted areas. This program channels most 
governmental funding for biotech in China, focusing primarily on the 
genetic engineering of animals and plants for high yield and quantity, 
the research and development of new medicines, vaccines and gene ther-
apies, and protein engineering for food industries.77 
In addition, China's National Center for Biotechnology Develop-
ment administers a RMB 7.4 million annual budget for biotechnology 
under the SSTC.78 Roughly 32% of that budget is devoted to pharma-
ceutical research, 8% for protein engineering research, 20% for commer-
cialization, and 32% for agricultural research.79 Foreign partnerships are 
also allowed to compete for funding in this program. 
The SSTC's Torch program, established in 1988, aims to commer-
cialize, industrialize, and globalize China's new technologies.80 The bi-
otech component of this program has focused on biopharmaceutical 
products for the creation of vaccines like hepatitis B, and anti tumor 
drugs.81 The Torch program also provides contacts for foreign compa-
nies interested in joint ventures and offers incentives to investors in the 
52 high tech zones that it has established across China. 82 
The Spark program was established in 1985 and has encouraged 
economic development in the rural areas of China through the applica-
tion of science and technology. 83 Spark grants loan packages and has a 
development center under the SSTC which matches proposals with 
grants and loans. 84 Because this program focuses on biotech outside the 
field of medicine in areas like bioagriculture, grain production, animal 
75. Id. 
76. Id. 
77. Id. 
78. Id. 
79. Beckman, supra note 68. 
80. Id. 
81. Id. 
82. Id. 
83. Id. 
84. Id. 
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husbandry, and storage technology,85 it has been particularly important 
in meeting the nutritional needs of China's approximately 1.2 billion 
people. 
China's last program under the SSTC is the National Natural Sci-
ence Foundation (hereinafter NNSFC), which promotes basic research in 
all science and technology. In 1993, the NNSFC had a total budget of 
$28 million, 14% of which was devoted to clinical medical sciences.86 
The NNSFC also launched a national genome project as part of its con-
tribution to international genome project in 1993.87 
Under all six of these programs, researchers submit their own 
projects to compete for funds allocated toward designated fields. These 
researchers are also expected to find external funding to supplement the 
slight decrease in governmental funding. China eventually plans to 
make external sources, such as international foundations and private 
firms bear the majority of financial responsibility and severely decrease 
government financing. 88 While the absence of governmental financing 
may lessen the government's control in determining the types of re-
search conducted, many private companies who bear the total fiscal cost 
without the benefit of total control will likely look elsewhere for busi-
ness. Therefore, if China follows through with its plans to completely 
cut government funding for biotechnology, and yet maintain restrictions 
on the type of biotech to be produced, it may be driving away the very 
industry it sought to create. The author is not suggesting, however, that 
the biotechnology industry be entirely unregulated by the government. 
Rather, until the industry is fully developed, China is in need of a bal-
ance between governmental and private control. 
In addition, China hosts 120 domestic biotech companies which 
commit only a small portion of funding to research. 89 Most of these 
companies rely on results published by the Chinese research community 
and foreign sources to produce the scientific portion of their products. 
Moreover, the Chinese government's attempts at transforming the econ-
omy into a market system have created special government financing 
programs for commercially viable products to work in cooperation with 
a biotech company.90 Thus, the government may transform research in-
stitutions into private labs that do work only on the products contracted 
85. Id. 
86. Id. 
87. China Enters Genome Research, B10TEcHNOLOGY Bus. NEws, Sept. 24, 1993. A gen-
ome is the complete set of haploid chromosome in an organism. 
88. Beckman, supra note 68. 
89. Id. 
90. Id. 
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for with the biotech companies. While this system may create immedi-
ate profits since it focuses only on commercially viable products, it may 
defeat the purpose of an applied research system. The special govern-
ment financing may also relegate China to simply producing products 
already known to be profitable, which likely stem from a foreign source, 
instead of being at the center of the development process and originating 
these products. 
A. FOREIGN FIRM INVOLVEMENT WITH CHINA'S BIOTECH INDUSTRY 
In the early to mid 1990' s, foreign firms began to envision enor-
mous investment opportunities in China for the biotechnological produc-
tion of drugs, food and chemicals. By 1994, analysts were predicting 
that the market for medical technology products in China would grow 
three to four times faster than industrialized countries.91 The same num-
bers were again forecasted for the years 1997-1999. 92 In 1996, China's 
medical technology market grew 28%, making it the fastest growing 
market in the world.93 As a result of this positive financial outlook, and 
despite fears regarding adequate intellectual property protection, the 
U.S., Europe and Japan have been competing vigorously for investment 
opportunities in China. 94 
The business device employed by foreign firms in China is almost 
exclusively a joint venture. The remainder of foreign-owned enterprises 
that choose not to pursue joint ventures in China, but still want a share 
of the Chinese market, will ordinarily attempt to launch their own prod-
ucts there. Many firms from the U.S., Europe and Japan have engaged 
in joint ventures and have decided to move their clinical trials, R&D, 
and manufacturing capacity overseas to avoid delays and to be near the 
markets where they first introduce their products.95 Foreign companies 
feel that these business relationships can prove beneficial by lowering 
research expenses, facility and manpower costs, and absorbing more ad-
vanced Chinese technology .96 A few private companies have contracted 
projects with Chinese institutions to take advantage of transgenic plant 
technology advances achieved with the aid of international coopera-
tion. 97 In addition, foreign biomed/biotech firms often view China as an 
91. Asia Fastest Growing Market, BIOCHEMICAL MARKET NEWSL. Jan. 1, 1994. 
92. Id. 
93. Market Research Studies: Expert market Devises Improving I997 Global Market, BI-
OMEDICAL MARKET NEWSL., Apr. 30, 1997. 
94. Id. 
95. Id. 
96. Beckman, supra, note 68. 
97. Id. 
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inexpensive place to conduct laborious processes which do not involve 
the transfer of their newest technology. 98 
The transfer of mainly older technology reduces some of the for-
eign companies' fears over intellectual property protection. Further-
more, conducting research with Chinese partners can facilitate a firm's 
product entrance into the Chinese market since many of the partners 
have relationships with the Ministry of Health.99 Similarly, complaints 
lodged with the local government from a joint venture are ordinarily 
acted upon with more vigor than those from purely foreign companies. 
Local favoritism to joint ventures occurs because the Chinese partner 
will typically have a relationship with various governmental agencies, 
whereas a foreign-owned enterprise likely has no ties to China at all. 
While the business opportunities in Chinese biotechnology appear 
endless, many Westerners warn that foreign firms need to be careful 
because the political system is not fully developed in China. For exam-
ple, one U.S. entrepreneur involved in the biomed/biotech industry was 
shocked to learn that one of his Chinese clients was forced to register 
with the police within 30 days if that person wanted to use the Internet 
or other online services. 100 Moreover, a company may have problems 
getting its hard currency out of China once it has been converted into 
local Renminbi. 101 Another concern regarding Chinese joint ventures is 
that since local manufacturers have not yet constructed high-tech ma-
chines capable of producing enzymes and similar biotech materials, this 
high cost equipment must be imported from the U.S. or Japan. 102 After 
considering importation, transportation and administration costs, cou-
pled with the frustration incurred from cultural clashes, setting up a joint 
venture in China does not come without a price. However, establishing 
a joint venture in China can nonetheless be a very lucrative business. 
Balancing the total expenses against low labor costs, beneficial tax cred-
its, and favorable regulatory practices generally results in increased 
profit margins. 
1. Sample Biotech Joint Ventures in China 
In 1993, Merck, a multinational pharmaceutical company that uses 
biotechnology, inaugurated a high-tech manufacturing plant in Beijing 
98. Id. 
99. Id. 
100. David Anast, Don't Throw our Chines Clients in Jail using the Interest is not a Crime, 
BIOMEDICAL MARKET NEwsL., Feb. 1, 1996. 
101. New Company Aims to Bridge the Gap between East and West, BIOTECHNOLOGY Bus. 
NEWS, June 3, 1994, at 13. 
102. Beckman, supra, note 68. 
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to produce its hepatitis B vaccine. 103 The joint Sino-American project 
sought to initiate Chinese production of Merck's HB Vax II to enable 
the country to fight one of its largest public health threats. 104 The fac-
tory was built in collaboration with China's National Vaccine and Serum 
Institute under the Ministry of Public Health and is able to produce 20 
million doses of anti-hepatitis vaccine. 105 Merck also established a sec-
ond manufacturing plant in the southern city of Shenzhen in 1994.106 
More recently, in 1996, the French genetic research company Gen-
set established a joint venture in Beijing with the Chinese Academy of 
Medical Sciences and Tang Freres, a French trading firm that specializes 
in Chinese medical and pharmaceutical fields. 107 The objective of the 
joint venture is to collect DNA from related and unrelated individuals 
affected with common diseases, conduct gene discovery research on 
such DNA in collaboration with Genset, and eventually market products 
based on these discoveries in China. 108 Genset is engaged in the system-
atic and comprehensive analysis of the human genome to identify and 
patent genes. Genset then applies its genomics technology to both dis-
cover drugs for the treatment of diseases and to enter into strategic part-
nerships with pharmaceutical companies for the development and 
marketing of these drugs. Genset has targeted such ailments as prostate 
cancer, schizophrenia, osteoporosis, psoriasis, and hypertension. Upon 
the creation of this joint venture, Genset's president remarked, " .. .it 
provides us with access to highly-characterized samples representing a 
wide range of diseases from the largest population in the world. The 
immense resources of China in medical and clinical research are an ideal 
complement for Genset large-scale technology." 109 Therefore, by the 
creation of this joint venture, Genset clearly regards China as the prover-
bial 'field of dreams' in the futuristic realm of biotechnology. 
Similarly, in 1997, Japan's Kirin Brewery Co. and China's Shang-
hai Kunpeng Investment Co. agreed to set up a joint venture in Shanghai 
to produce and market two drugs. 110 The first drug, Espo, will be used 
to treat renal anemia and the second drug, Gran, is a granulocyte colony 
stimulating factor. Kirin had previously been exporting the drugs to 
Beijing, Shanghai, and Guangzhou through its marketing base in Hong 
103. Merck opens hepatitis B plant, BIOTECHNOLOGY Bus. NEWS, Oct. 21, 1993, at 9. 
104. Id. 
105. Id. 
106. Id. 
107. Genset and Chinese Academy to Enter Joint Venture for Genomics, WORLDWIDE Br-
OTECH, Dec. 1, 1996. 
108. Id. 
109. Id. 
110. Kirin in Shanghai Venture, BIOTECHNOLOGY NEWSWATCH, June 2, 1997, at 6. 
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Kong. Now, however, the joint venture also plans to construct a basic 
research laboratory and a drug manufacturing facility for herbal 
medicines by 2003. 111 
Thus, by establishing joint ventures in China, foreign firms are ac-
know I edging that both the immense size of the Chinese market and the 
capability of the preexisting Chinese medical facilities have created 
favorable arenas in which to launch their biomed/biotech products. On 
the opposite side of the bargaining table, China has been able to absorb 
numerous quantities of foreign technology, insights onto foreign exper-
tise, and has received billions in foreign investment by forming joint 
ventures. Furthermore, the profits generated by the biotech industry will 
help fuel the Chinese economy and thereby contribute to an increased 
standard of living. 
2. Foreign use of Chinese Herbs to Produce New Drugs 
An interesting twist on foreign business relations with China has 
occurred through the increasing application of biotechnological 
processes on plants traditionally used in Chinese medicine to produce 
new drugs. Thus, herbal medicines originated by the Chinese are now 
being adapted through biotechnology to produce drugs capable of fight-
ing various diseases. Unless the Chinese institute formal agreements 
that ensure adequate compensation for the use of their flora and fauna, 
foreign firms are likely to exploit China's natural habitat without fairly 
distributing any of the profits that have been accrued from the new bi-
opharmaceuticals. The foreign use of Chinese plants to produce bi-
opharmaceuticals underscores China's momentary failure to 
commercialize its own products, export its technology into the W estem 
world, and to bring in developing W estem technology for its own mar-
ket. To date, China has acknowledged some of these failures by con-
structing joint ventures with foreign firms so that they can not only reap 
a share of the profits from the use of their plant/animal life but also gain 
an insight onto the technology employed to produce the new drugs. 
For example, a joint venture was established by Global Pharm Ltd, 
a Bermuda based company, with Northeast No. 6 Pharmaceutical Fac-
tory in Shen Yang, China. 112 Global Pharm began its operations in 1995 
and has sought to expand the market for Chinese government approved 
human-use pharmaceuticals. The company has also planned to select 
and acquire unrecognized Chinese pharmaceuticals for development in 
111. Id. 
112. T Cell looks to China, BIOTECHNOLOGY Bus. Ni;:ws, June 23, 1995, at 7. 
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other territories. 113 Like many foreign companies, Global Pharm chose 
China for access to its large, emerging market opportunities in therapeu-
tic products, as well as access to new product candidates for develop-
ment outside China. The first product to be marketed by the venture is 
for the treatment of hypertension and microcirculation disorders. 114 The 
drug is a synthetic copy of the active ingredient found in a Chinese 
herb. 115 
The British firm Xenova has signed drug discovery agreements 
with the Institute of Medicinal Plant Development (hereinafter IM-
PLAD) and the Institute of Botany, both in the Peoples Republic of 
China. 116 The agreement establishes that IMPLAD will supply plant ex-
tracts and the Institute of Botany will supply a combination of plant 
extracts and phytochemicals to Xenova. The British firm will then run 
screening tests to identify potential drug activities against illnesses such 
as cancer, cardiovascular disease, and immune-inflammatory disor-
ders.117 Thus, Xenova uses its biotechnologies to formulate new drugs 
from natural sources. The arrangement further provides that Xenova 
will have marketing rights outside China for any therapeutics discov-
ered, and China will both retain exclusive internal marketing rights and 
receive royalties on Xenova' s sales. 118 
In the early 1980's, UCLA biochemists received several ancient 
lotus seeds from the Beijing Institute of Botany that were recovered 
from a lake in Pulantien, China.119 The UCLA scientists have sine~ dis-
covered a powerful genetic system in the seeds to delay its aging. 120 
Upon examining the lotus embryos, the scientists found a protein repair 
enzyme which limits the accumulation of damaged proteins and helps 
the plant adapt to environmental stresses. 121 The enzyme, known as 
MT, is now being employed on longevity experiments with mice. 122 
For the most part, China has been able to control the foreign manip-
ulation of traditional Chinese herbs by either forming joint ventures or 
contracting for a share of the profits derived from foreign biomedical 
113. Id. 
114. Id. 
115. Id. 
116. Xenova looks at Chinese Medicinal Plants for New Drugs, GENETIC TECH. NEWS TECH. 
INSIGHTS, INc, Dec. 1, 1992. 
117. Id. 
118. Id. 
119. After Thousand-Year Sleep, Lotus Sprouts Chemistry of Longevity Theories, BIOTECH-
NOLOGY NEWSWATCH, Jan.1, 1996, at 1. 
120. Id. 
121. Id. 
122. Id. 
17
et al.: A Dynasty Weaned From Biotechnology: The Emerging Face of China
Published by SURFACE, 1998
168 Syracuse J. lnt'l L. & Com. [Vol. 26:151 
enterprises. Once the industry has a few years to grow, China may be 
able to exclusively transform materials from their natural habitat into 
new pharmaceuticals without the need for any foreign control. If China 
can amass enough capital, establish strong research teams, and produce 
qualified economists, the only remaining foreign component that is re-
quired to construct biopharmaceuticals is high tech machinery. 
B. The Effect of the Reunification with Hong Kong on China's 
Biotech Industry 
In the late 1980' s, biotechnology was identified as one of the major 
areas in which new profitable business opportunities could be generated 
in Hong Kong. Shortly thereafter, the Hong Kong Institute of Biotech-
nology (hereinafter HKIB) emerged on the shore of Tolo Harbor as a 
joint venture operation with a major U.S. pharmaceutical company, 
Syntex Corporation, for the discovery of novel therapeutic agents based 
on Chinese herbal medicines. 123 The joint venture had the express task 
of trying to merge ancient Chinese remedies with W estem technology to 
find novel drugs to cure or treat twentieth century diseases. 124 Accord-
ingly, the institute has signed an agreement with a Chinese research fa-
cility to internationally market a compound discovered in China which 
may help to treat cancer patients. 125 More importantly, however, the 
founders of HKIB viewed its formation as a link to biotechnology bases 
in Asia. 126 
Besides HKIB' s major project, some of China's leading scientists 
in genetic engineering, together with a third group of scientists in Hous-
ton, are collaborating on a project headed by HKIB's founding director. 
The group seeks to develop new drugs to combat neurological disorders 
such as epilepsy, Alzheimer's disease, Parkinson's disease, depression 
and substance abuse. 127 A major part of the research includes the trans-
fer of human neurological genes into mouse cells to construct specific 
genetic engineered cell lines. 128 The scientists hope that the cloned cells 
will be able to shed light on the molecular basis of many brain functions. 
They also hope that the cells will be useful for the discovery of new 
pharmaceutical agents against a number of brain and cardiovascular 
diseases. 
123. Jonathan Lange, Brainstorming the Brain Cells, WORLDWIDE BmrncH, Sept. 1, 1992. 
124. Id. 
125. Id. 
126. Id. 
127. Id. 
128. Id. 
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Based on the success of HKIB and similar companies, researchers 
at the Massachusetts Institute of Technology announced a study in early 
1997 that Hong Kong would be a major player in the field of bi-
opharmaceuticals produced from traditional Chinese medicines. 129 The 
researchers at MIT believed that Hong Kong's success would be driven 
by the historical acceptance of these medicines and the extensive data 
which has been collected about them.13° They cited that another impor-
tant advantage Hong Kong has over its rivals is its close proximity to 
China. 131 The close link between the territory and the mainland has ena-
bled local companies to draw on the expansive breadth of knowledge 
that the Chinese have amassed over the centuries regarding the proper 
use of their medicinal plants. 
A second event in early 1997 made Hong Kong a focus site for 
biotechnology. The Beijing Institute of Developmental Biology at the 
Chinese Academy of Sciences decided to collaborate with the University 
of Hong Kong to combine China's animal husbandry expertise with 
Hong Kong's research skills and equipment. 132 The goal of the collabo-
ration was the development of improved gene targeting methods in cre-
ating transgenic animals. 133 China had been genetically altering pigs 
and goats to produce drugs from their milk and sought to increase the 
scope of their research capabilities by forming the agreement. 134 
Finally, on the evening of June 30, 1997, the world watched the 
official ceremonies and fireworks celebrations that marked Hong Kong's 
return to Chinese control. Although there has been much speculation on 
the future of Hong Kong, the Chinese government has promised to 
maintain 'one country, two systems' for the next fifty years. In fact, 
China has erected enormous advertising billboards on the southern bor-
der between Hong Kong and Shenzhen which emphatically announce 
that 'Hong Kong will have a more beautiful future.' The same slogan 
can even be glimpsed on t-shirts sold to tourists in the Temple Street 
night market. 
Although there are many skeptics on China's ability to economi-
cally handle Hong Kong, the realm of biotechnology appears more se-
cure. Since China sought to absorb Hong Kong's biomedical research 
capabilities before the handover occurred, and since China is intent on 
129. Biotechnology Profile: A New industry Mushrooms, HONG KONG INDUSTRIALIST, May 
1, 1997. 
130. Id. 
131. Id. 
132. China, Hong Kong to Collaborate, BIOTECHNOLOGY NEwswATCH, Mar. 17, 1997. 
133. Id. 
134. Id. 
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the success of its own biotech industry, it is likely that the Chinese gov-
ernment will attempt to properly maintain Hong Kong's businesses and 
research facilities. Moreover, the Chinese will increasingly rely upon 
Hong Kong's biotech facilities after the handover to support their own 
growing biotech industry. Although Shanghai will be a top contender 
for receiving imports, Hong Kong's port capabilities will ease China's 
former import hassles because once the technologies reach Hong Kong, 
they can be channeled into China with reduced customs procedures. 
China may also be able to learn from the structure of Hong Kong's more 
Western style biotech system while perfecting their own. Therefore, the 
biotech development that occurred in Hong Kong during the years pre-
ceding the handover will only benefit China's expanding system. 
1. The Biotechnological Impact of the Bird Flu in Hong Kong 
In the months following the handover, however, Hong Kong suf-
fered from what has become popularly known as the "bird flu." Since 
the onset of the outbreak, there have been a total of eighteen patients 
diagnosed with the virus, six of whom have died. 135Because Hong Kong 
and southern China have been historically characterized as breeding 
grounds for new strains of influenza, the avian virus spread fears of a 
worldwide epidemic. 136 As a result of these rising fears, the National 
Institutes of Health awarded Protein Sciences Corporation, a U.S. com-
pany, the vaccine contract in December 1997, after receiving an urgent 
request from Hong Kong. 137 By February 3, 1998, the biotechnology 
company successfully produced a genetically engineered vaccine to 
combat the virus. 138 Chief Executive Officer of Protein Sciences, Daniel 
D. Adams, commented, [Through the use of biotechnology] "it is now 
feasible to respond in a timely fashion to emerging new influenza virus 
strains and to decide on which strains to include in the annual flu vac-
cine much closer to the time the vaccine is needed." 139 Although Hong 
Kong required the aid of U.S. biotechnology companies in order to pro-
duce a vaccine for the current strain of avain virus, it is possible that in 
the future, Hong Kong will have the capacity from its own biotech com-
panies to handle another outbreak. Because new strains of influenza 
135. Marilyn Chase, Flu Viruses HitHard As Researches Plan Their Next Defense, WALL 
ST. J., Jan. 19, 1998, at Bl. 
136. Craig S. Smith, Hong Kong Halts Live Chicken Imports From China Due To Avian Flu 
Virus, WALL ST. J., Dec. 16, 1997, at B7. 
137. Emergency Human Vaccine Against Hong Kong H5Nl Influenza "Bird Flu" Devel-
oped by Connecticut Biotechnology Company (visited Mar. 1, 1998) <http:// 
www.proteinsciences.com>. 
138. Id. 
139. Id. 
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commonly occur in Hong Kong and Southern China 140 , the Chinese 
have an incentive to form biomedical companies which can quickly pro-
duce vaccines. These vaccines can also be used to prevent infection in 
animals and break the chain of transmission from animals to humans. 141 
Since the current bird flu was able to spread among thousands of chick-
ens before being discovered, subsequently requiring their mass slaugh-
ter,142 Hong Kong has suffered a significant economic loss. If, in the 
future, China can focus its energies on establishing successful biotech 
companies, substantial economic loss caused by influenza could be 
prevented. 
V. CONCLUSION 
Based on China's stunning capabilities to not only transform an 
entire body of law, but also to shape a high tech industry within a mere 
decade, the Chinese will likely disarm the world in the coming years 
with its biomed/biotech industry. China has strategically recognized the 
need for foreign support in getting its biotech industry off the ground. 
Once the Chinese, however, gain the facilities to produce the high tech 
equipment required for the formation of biomedical materials, they will 
no longer have to wholly rely upon foreign investment. Moreover, the 
Chinese are host to an enormous array of naturally growing flora and 
fauna which is currently the fastest developing sector of biomedicine. 
When the standard of living increases in China, the Chinese will have 
the first opportunity to tap a market of 1.2+ billion people. The Chinese 
population, afflicted in large numbers with hepatitis B and other diseases 
due to malnutrition and unsanitary living conditions, will doubtlessly 
require the new pharmaceuticals that China is manufacturing. In addi-
tion, China will be able to market the new biopharmaceuticals globally. 
If the Chinese market their drugs at a favorable time, as the trend is now 
shifting to favor Eastern style medicine, China may be extremely suc-
cessful in the biomedical field. While China's success admittedly 
hinges on many 'ifs', the development of biotechnology in China has 
shown enormous growth in a very short period of time. As long as 
China can maintain a similar rate of growth in the next decade, then 
140. Smith, supra note 136. 
141. Emergency Human Vaccine Against Hong Kong H5Nl Influenza "Bird Flu" Devel-
oped by Connecticut Biotechnology Company (visited Mar. 1, 1998) <http:// 
www.proteinsciences.com>. 
142. Peter Stein, In Hong Kong, Chicken Slaughter Fails to Kill Fears, WALL ST. J., Jan. 5, 
1998 at A17. 
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biotechnology may very well be the field that restores China to its for-
mer magnificence. 
Leslie Cataldo 
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